# **Human Papillomavirus Vaccines Session**

Peter Szilagyi, MD, MPH
Chair, ACIP HPV Vaccines Work Group

Advisory Committee on Immunization Practices
October 25, 2017

## 2-Dose HPV Vaccine Recommendations

- Last HPV vaccine session at ACIP October 2016
- □ ACIP recommended 2-dose schedule for persons initiating series before age 15 yrs
- MMWR Policy Note December 16, 2016
  - Use of a 2-Dose Schedule for Human Papillomavirus (HPV) Vaccination: Updated Recommendations of the Advisory Committee on Immunization Practices

Morbidity and Mortality Weekly Report

Use of a 2-Dose Schedule for Human Papillomavirus Vaccination — Updated Recommendations of the Advisory Committee on Immunization Practices

Elissa Meites, MD1; Allison Kempe, MD2,3; Lauri E. Markowitz, MD1

#### Introduction

Vaccination against human papillomavirus (HPV) is recommended to prevent HPV infections and HPV-associated diseases, including cancers. Routine vaccination at age 11 or 12 years has been recommended by the Advisory Committee on Immunization Practices (ACIP) since 2006 for females and since 2011 for males (1,2). This report provides recommendations and guidance regarding use of HPV vaccines and updates ACIP HPV vaccination recommendations previously published in 2014 and 2015 (1,2). This report includes new recommendations for use of a 2-dose schedule for girls and

Three HPV vaccines are licensed for use in the United States. All are noninfectious. Quadrivalent and 9-valent HPV vaccines (4vHPV and 9vHPV, Gardasil and Gardasil 9, Merck and Co, Inc., Whitehouse Station, New Jersey) are licensed for use in females and males aged 9 through 26 years (1). Bivalent HPV vaccine (2vHPV, Cervarix, GlaxoSmithKline, Rixensart, Belgium) is licensed for use in females aged 9 through 25 years (1). As of late 2016, only 9vHPV is being distributed in the United States. The majority of all HPV-associated cancers are caused by HPV 16 or 18, types targeted by all three vaccines. In addition, 4vHPV targets HPV 6 and 11, types that cause

MMWR 2016; 65(49):1405–1408 www.cdc.gov/vaccines/hcp/acip-recs/vaccspecific/hpv.html

# **ACIP HPV Vaccines Work Group Activities Since October 2016**

- Change in Work Group chair
- Held ~monthly conference calls
- Discussed potential policy issues
  - Routine target age wording: "9 –12 yrs" vs "11–12 yrs; the vaccination series can be started at age 9 yrs"
  - Harmonization of upper age for male and female recommendation
- □ Reviewed other topics/data
  - Footnotes for child/adolescent and adult schedules
  - 9-valent HPV vaccine safety data

# **HPV Vaccines Session Today**

■ Updates - ACIP Work Group and other HPV vaccine related issues

## **ACIP HPV Vaccines Work Group**

#### **ACIP Members**

Peter Szilagyi (Chair) Cynthia Pellegrini Jose Romero

#### Ex Officio Members

Jeff Roberts (FDA)
Joohee Lee (FDA)

#### **CDC Lead**

Lauri Markowitz

#### **Liaison Representatives**

Shelley Deeks (NACCI)

Linda Eckert (ACOG)

Sandra Fryhofer (ACP)

Amy Middleman (SAHM)

Chris Nyquist (AAP)

Sean O'Leary (PIDS)

Margot Savoy (AAFP)

Patricia Whitley-Williams (NMA)

Jane Zucker (AIM)

#### Consultants

Joseph Bocchini

Tamera Coyne-Beasley

John Douglas

Sam Katz

Allison Kempe

Aimee Kreimer (NCI)

Debbie Saslow (ACS)

Rodney Willoughby

### **CDC Contributors**

Jorge Arana

Harrell Chesson

**Robin Curtis** 

Julianne Gee

Elissa Meites

Jeanne Santoli

Mona Saraiya

**Shannon Stokley** 

Lakshmi Sukumaran

Elizabeth Unger